Lorenz; Douglas Alan
Patent Applications and Registrations
Patent applications and USPTO patent grants for Lorenz; Douglas Alan.The latest application filed is for "formulations of enzalutamide".
- Lorenz; Douglas Alan - Bend OR
| Patent | Date |
|---|---|
| Formulations Of Enzalutamide App 20200060976 - Lorenz; Douglas Alan ; et al. | 2020-02-27 |
| Compositions and methods for the treatment of neurodegenerative and other diseases Grant 10,398,713 - Reeder , et al. Sep | 2019-09-03 |
| Formulations Of Enzalutamide App 20190209476 - Lorenz; Douglas Alan ; et al. | 2019-07-11 |
| Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases App 20190015431 - Reeder; Thaddeus Cromwell ; et al. | 2019-01-17 |
| Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1- -yl}-pyrimidine Grant 10,098,843 - McWherter , et al. October 16, 2 | 2018-10-16 |
| Compositions and methods for the treatment of neurodegenerative and other diseases Grant 9,980,978 - Reeder , et al. May 29, 2 | 2018-05-29 |
| Compositions and methods for the treatment of neurodegenerative and other diseases Grant 9,974,798 - Reeder , et al. May 22, 2 | 2018-05-22 |
| Compositions and methods for the treatment of neurodegenerative and other diseases Grant 9,918,997 - Reeder , et al. March 20, 2 | 2018-03-20 |
| Formulations Of Enzalutamide App 20170224624 - Lorenz; Douglas Alan ; et al. | 2017-08-10 |
| Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases App 20170165279 - Reeder; Thaddeus Cromwell ; et al. | 2017-06-15 |
| Compositions And Methods For The Treatment Of Neurodegenerative And Other Diseases App 20170079991 - Reeder; Thaddeus Cromwell ; et al. | 2017-03-23 |
| Compositions And Methods For The Treatment Of Neurodegenerative And Other Diseases App 20170079990 - Reeder; Thaddeus Cromwell ; et al. | 2017-03-23 |
| Compositions and methods for the treatment of neurodegenerative and other diseases Grant 9,597,339 - Reeder , et al. March 21, 2 | 2017-03-21 |
| Formulations Of Enzalutamide App 20170027910 - Lorenz; Douglas Alan ; et al. | 2017-02-02 |
| Compositions Of 5-ethyl-2--pyrimidine App 20160213618 - McWherter; Charles A. ; et al. | 2016-07-28 |
| Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1- -yl}-pyrimidine Grant 9,241,924 - McWherter , et al. January 26, 2 | 2016-01-26 |
| Formulations Of Enzalutamide App 20140378517 - Lorenz; Douglas Alan ; et al. | 2014-12-25 |
| Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases App 20140221321 - Reeder; Thaddeus Cromwell ; et al. | 2014-08-07 |
| Formulations Of Enzalutamide App 20140179749 - Lorenz; Douglas Alan ; et al. | 2014-06-26 |
| Formulations Of Enzalutamide App 20140100256 - Lorenz; Douglas Alan ; et al. | 2014-04-10 |
| Spray dried formulation Grant 8,372,836 - Ketner , et al. February 12, 2 | 2013-02-12 |
| Compositions Of 5-ethyl-2--pyrimidine App 20110318418 - McWherter; Charles A. ; et al. | 2011-12-29 |
| Spray dried formulation App 20100029667 - Ketner; Rodney James ; et al. | 2010-02-04 |
| Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor App 20080274192 - Friesen; Dwayne Thomas ; et al. | 2008-11-06 |
| Compositions comprising an HIV protease inhibitor App 20050129772 - Smith, Scott Wendell ; et al. | 2005-06-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 